Glycerophospholipids pathways and chromosomal instability in gastric cancer: Global lipidomics analysis

Table 1 Clinical characteristics of the study

Term	TCGA system
	CIN	Non-CIN
Number	9	9
Age (median yr, range)	68.1 (56-79)	66.9 (52-87)
Sex (male/female)	7/2	5/4
Size (cm)	4.0 (1.8-6.9)	5.4 (2.3-11.6)
Lauren's classification
Intestinal type	6	1
Diffuse type	0	5
Mixed type	3	3
Stage
I	1	0
II	2	2
III	5	6
IV	1	1

TCGA: The Cancer Genome Atlas; CIN: Chromosomal instability.

Table 2 Compound list (n = 32) of the significant changes between tumor and normal group using electrospray ionization positive and negative modes

Catalog	Putative ID	RT (min)	m/z	Adduct ion	VIP	FC
TG	TG(54:3)	15.6	902.8202	[M+NH4]+	2.3	0.5
	TG(52:4)	15.1	872.7729	[M+NH4]+	3.2	0.4
	TG(52:2)	15.6	876.8048	[M+NH4]+	3.2	0.5
	TG(50:3)	15.0	846.7568	[M+NH4]+	2.9	0.3
	TG(50:2)	15.3	848.7722	[M+NH4]+	3.3	0.4
SM	SM(d18:1/24:0)	13.3	815.7015	[M+H]+	1.6	1.3
	SM(d18:1/18:0)	7.1	775.5980	[M+FA-H]-	1.7	0.7
	SM(d18:0/22:0)	9.9	811.6627	[M+H]+	2.1	1.3
	SM(d18:0/16:0)	6.0	705.5912	[M+H]+	1.0	1.4
PS	PS(P-18:0/22:6)	9.2	818.5336	[M-H]-	1.0	0.7
PI	PI(22:3/16:0)	6.1	887.5682	[M-H]-	1.4	1.9
	PI(20:4/16:0)	4.2	857.5202	[M-H]-	1.4	0.6
	PI(16:0/18:2)	4.4	833.520	[M-H]-	3.0	0.8
PE	PE(P-18:1/20:4)	7.1	748.5279	[M-H]-	2.5	0.7
	PE(P-18:0/18:2)	9.7	726.5437	[M-H]-	2.5	1.7
	PE(P-16:0/18:2)	7.3	698.5117	[M-H]-	4.0	1.9
	PE(20:4/16:0)	6.2	740.5237	[M+H]+	3.6	0.4
	PE(18:2/18:1)	6.6	740.5221	[M-H]-	2.3	0.4
	PE(18:2/16:0)	6.4	714.5061	[M-H]-	2.2	0.4
	PE(18:1/18:1)	8.2	742.5385	[M-H]-	2.4	0.6
PC	PC(38:4)	6.4	810.6034	[M+H]+	2.6	1.7
	PC(34:3)	4.8	756.5561	[M+H]+	14.2	1.5
	PC(30:0)	5.5	706.5394	[M+H]+	2.9	2.4
	PC(18:2/16:0)	6.0	758.5702	[M+H]+	3.0	0.6
	PC(18:0/20:3)	8.6	812.6191	[M+H]+	3.3	3.6
	PC(18:0/18:1)	9.8	832.6090	[M+FA-H]-	7.9	1.3
	PC (16:1/16:0)	5.6	776.5467	[M+FA-H]-	1.2	2.0
	PC (16:0/16:0)	7.3	734.5717	[M+H]+	1.5	1.4
LysoPC	LysoPC (16:0)	1.2	496.3395	[M+H]+	3.1	0.7
Ceramide	Cer (d18:1/24:0)	13.9	694.6341	[M+FA-H]-	1.6	1.6
carnitine	Linoleyl carnitine (C18:2)	1.0	424.3408	[M+H]+	1.2	0.6
	Oleoyl carnitine (C18:1)	1.2	426.3560	[M+H]+	1.1	0.8

All P value < 0.05. The protonated [M+H]⁺ and anionized adduct [M+NH₄]⁺ in positive mode, and deprotonated [M-H]^- and formic acid adduct [M+FA-H]^- in negative ion mode. FC: Fold changes (tumor/normal); LyPC: Lysophosphocholine; PC: Phosphocholine; PE: Phosphatidylethanolamine; SM: Sphingomyelin; PI: Phosphoinositol; TG: Triglyceride; VIP: Variable importance in projection.

Table 3 Compound list (n = 17) of the significant changes between chromosomal instability and non-chromosomal instability groups using electrospray ionization positive and negative modes

Catalog	Putative ID	RT (min)	m/z	Adduct ion	VIP	FC
SM	SM(d18:1/18:0)	7.2	731.6077	[M+H]+	5.8	0.49
PI	PI(22:6/18:0)	5.1	909.554	[M-H]-	1.6	1.53
	PI(22:3/16:0)	6.1	887.568	[M-H]-	3.0	1.75
PE	PE(P-18:0/18:2)	9.7	726.544	[M-H]-	2.8	1.92
	PE(P-16:0/20:5)	5.8	720.499	[M-H]-	2.8	2.15
	PE(37:4)	5.8	754.5381	[M+H]+	2.9	1.77
	PE(22:6/18:1)	5.8	788.523	[M-H]-	1.9	1.43
	PE(18:2/16:0)	6.5	716.5233	[M+H]+	2.7	1.52
PC	PC(38:6)	6.5	806.571	[M+H]+	3.2	2.06
	PC(38:4)	6.7	810.6041	[M+H]+	5.9	2.34
	PC(36:5)	4.8	780.5556	[M+H]+	5.7	2.30
	PC(33:2)	5.3	744.5562	[M+H]+	3.2	1.73
	PC(33:1)	6.5	746.5715	[M+H]+	3.2	1.59
	PC(30:0)	5.5	706.5394	[M+H]+	4.6	1.89
	PC(16:1/16:1)	4.6	730.5399	[M+H]+	4.1	1.98
	PC(16:1/16:0)	5.6	776.547	[M+FA-H]-	4.3	1.46
DG	DG(38:4)	12.6	667.5287	[M+Na]+	1.6	0.66

All P value < 0.05. The protonated [M+H]⁺ and sodium adduct [M+Na]⁺ in positive mode, and deprotonated [M-H]^- and formic acid adduct [M+FA-H]^- in negative ion mode. FC: Fold changes [Chromosomal instability (CIN)/non-CIN]; PC: Phosphocholine; PE: Phosphatidylethanolamine; PI: Phosphatidylinositol; SM: Sphingomyelin; DG: Diglyceride; VIP: Variable importance in projection.